Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glimepiride (1mg) + Metformin (500mg) SR Bilayered Smart Tablet
Therapeutic Category
Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*15
Price
₹102/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Gimtype M1 is a bilayered smart tablet specifically formulated for the effective management of type 2 diabetes mellitus. This innovative combination includes Glimepiride (1 mg) and Metformin (500 mg) sustained release (SR), designed to provide a comprehensive approach to controlling blood glucose levels in patients with diabetes.
Glimepiride, a member of the sulfonylurea class, works by stimulating the pancreas to release insulin, which is essential for lowering blood sugar levels. This mechanism is particularly effective in managing postprandial glucose levels, helping to prevent spikes in blood sugar after meals. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity in peripheral tissues and reduces hepatic glucose production. The sustained release formulation of Metformin ensures a gradual release of the medication, which helps maintain stable blood glucose levels throughout the day while minimizing gastrointestinal side effects.
The combination of Glimepiride and Metformin in Gimtype M1 not only aids in achieving better glycemic control but also helps reduce the risk of diabetes-related complications. This dual-action approach is especially beneficial for patients who may not achieve adequate control with Metformin alone. By addressing multiple pathways involved in glucose regulation, Gimtype M1 provides a more effective solution for managing type 2 diabetes.
Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia is also a risk, especially if meals are missed or if there is increased physical activity.
Gimtype M1 is indicated for the management of type 2 diabetes mellitus, particularly in conjunction with diet and exercise.
Consult your healthcare provider before starting this medication, especially if you have a history of kidney or liver disease.
Store Gimtype M1 tablets in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children
Composition : Glibenclamide I.P. 5mg + Metformin Hydrochloride I.P. 500mg + Pioglitazone Hydrochloride I.P. 15mg Tablets
Composition : Glimepiride (1mg) Tablet
Composition : Glimepiride (2mg) Tablet
Composition : Glimepiride 1mg + Metformin 500mg + Pioglitazone 15mg Bi-Layered Tablets
Composition : Glimepiride 2mg + Metformin Hydrochloride I.P. 500mg + Pioglitazone 15mg Bi-Layered Tablets
Composition : Gliclazide 80mg + Metformin Hydrochloride I.P. 500mg Tablets
Composition : Dapagliflozin 10mg Tablets
Composition : Empagliflozin (10mg) Tablet
Composition : Empagliflozin (25mg) Tablet
Composition : Empagliflozin (10mg) + Sitagliptin 100mg
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This combination has strong demand in the modern anti-diabetic and chronic care segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners focusing on advanced diabetes management portfolios.
Medical distributors and agencies can benefit from consistent demand for management of Type 2 Diabetes Mellitus, insulin resistance, and long-term glycemic control requiring sustained therapy. Glimepiride 1mg stimulates insulin secretion from pancreatic beta cells Metformin 500mg SR improves insulin sensitivity and reduces hepatic glucose production with sustained release for better control Bilayered smart technology supports better absorption, prolonged action, and improved patient compliance This makes it a strong and modern diabetes-care formulation.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for this advanced bilayered anti-diabetic tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong physician preference for SR formulations, high diabetic patient demand, long-term recurring sales, stable chronic-care market, reliable supply chain support, and good margins in anti-diabetic medicines.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.